Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...

Two-year real-world data highlight strong drug survival and effectiveness of bimekizumab in plaque psoriasis. Learn more ...

Reader's DigestHome Remedies for Eczema and Psoriasis ReliefSave money on expensive skin care treatments and try these homemade remedies first. Plaque psoriasis is a skin disease that causes raised ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis—often mistaken for dry skin or ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis. Read more here, ...

In the adolescent subgroup, 84.1% of patients treated with icotrokinra achieved IGA scores of 0/1 and 70.5% achieved PASI 90, compared with 27.3% and 13.6% receiving placebo, respectively, at week 16.

Alisha Bridges, 36, knows what it feels like to be treated differently because of how she looks. Since elementary school, Alisha has struggled with severe plaque psoriasis—a condition which causes ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...